Par Drugs & Chemicals Ltd
NSE: PAR
Par Drugs & Chemicals Ltd (PAR) is a Diversified company listed on NSE: PAR. With a market cap of ₹102 Cr and ROCE of 16.5%, ROE of 12.4%, it operates in the Indian Diversified sector.
₹83.2
52W: ₹78 — ₹122
PE 7.83 · Book ₹91 · -9% vs bookMarket Cap₹102 Cr
Stock P/E7.83Price to Earnings
ROCE16.5%Return on Capital
ROE12.4%Return on Equity
Div. Yield0%Face Value ₹10
Strengths
- +Company is almost debt free.
- +Stock is trading at 0.92 times its book value
Weaknesses
- −Though the company is reporting repeated profits, it is not paying out dividend
- −The company has delivered a poor sales growth of 11.3% over past five years.
Shareholding Pattern
Promoters73.41%
FIIs0%
DIIs0%
Public26.59%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 74.21% | 73.37%▼0.8 | 73.37% | 73.37% | 73.37% | 73.37% | 73.41%▲0.0 | 73.41% |
| FIIs | 0.32% | 0.09%▼0.2 | 0%▼0.1 | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 25.47% | 26.54%▲1.1 | 26.63%▲0.1 | 26.63% | 26.63% | 26.63% | 26.59%▼0.0 | 26.59% |
Financial Statements
| Metric | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 24 | 22.82 | 22.61 | 34.66 | 21.38 | 22.33 | 26.05 | 28.66 | 29.34 | 19.61 |
| Expenses | 18.77 | 16.72 | 18.37 | 23.25 | 19.95 | 19.9 | 22.49 | 22.6 | 23.29 | 18.17 |
| Operating Profit | 5.23 | 6.1 | 4.24 | 11.41 | 1.43 | 2.43 | 3.56 | 6.06 | 6.05 | 1.44 |
| OPM % | 21.79% | 26.73% | 18.75% | 32.92% | 6.69% | 10.88% | 13.67% | 21.14% | 20.62% | 7.34% |
| Net Profit | 3.42 | 3.72 | 2.53 | 8.6 | 0.58 | 1.65 | 3.33 | 4.13 | 4.8 | 0.85 |
| EPS ₹ | 2.78 | 3.02 | 2.06 | 6.99 | 0.47 | 1.34 | 2.71 | 3.36 | 3.9 | 0.69 |
AI Insights
Revenue Trend
Mar 2026 revenue at ₹104Cr, up 3% YoY. OPM at 17%.
Debt Position
Borrowings at ₹0Cr. Debt-to-equity ratio: 0.00x. Healthy balance sheet.
Capex Cycle
CWIP at ₹1Cr (3% of fixed assets). Moderate ongoing capital expenditure.
Institutional Flow
DIIs: 0% (+0.00pp change). FIIs: 0% (+0.00pp change). Promoters hold 73.41%.
Margin & Efficiency
ROCE improving from 10% (Mar 2015) to 17% (Mar 2026). Working capital days: 31.
Valuation
PE 7.83x with 16.5% ROCE. Price is -9% above book value of ₹91. Dividend yield: 0%.
Recent Announcements
- Copy of Newspaper Publication 15 May 2026 - Submitted newspaper cuttings for standalone audited results for quarter and year ended March 31, 2026.
- Outcome of Board Meeting 14 May 2026 - Board approved FY26 audited results; SEBI restrained proposed business transfer arrangement.
- Updates 14 May 2026 - Board approved FY26 audited results; revenue ₹103.66 crore, profit ₹13.11 crore, unmodified audit opinion.
- Updates 14 May 2026 - Board approved audited FY26 results on 14 May 2026; auditor gave unmodified opinion.
- Outcome of Board Meeting 14 May 2026 - Board approved FY2025-26 audited results on 14 May 2026; auditor issued unmodified opinion.
- Financial Year 2025 from nse
- Financial Year 2024 from nse
- Financial Year 2023 from nse